

Christian Hermann Ottensmeier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8913524/publications.pdf>

Version: 2024-02-01

234
papers

38,604
citations

18887

64
h-index

3343

190
g-index

249
all docs

249
docs citations

249
times ranked

47460
citing authors

#	ARTICLE	IF	CITATIONS
1	Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. <i>Neuroendocrinology</i> , 2022, 112, 370-383.	1.2	5
2	CD8 T cell-mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	5
3	Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. <i>Melanoma Research</i> , 2022, 32, 103-111.	0.6	8
4	Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e041961.	0.8	6
5	Targeting the tumor mutanome for personalized vaccination in a TMB low non-small cell lung cancer. , 2022, 10, e003821.		12
6	HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 131.	3.5	9
7	Changes in Gene Expression Patterns in the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Under Chemoradiotherapy Depend on Response. <i>Frontiers in Oncology</i> , 2022, 12, 862694.	1.3	1
8	Systemic therapy for pre-treated malignant mesothelioma: A systematic review, meta-analysis and network meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2022, 166, 287-299.	1.3	7
9	CD33 Expression on Peripheral Blood Monocytes Predicts Efficacy of Anti-PD-1 Immunotherapy Against Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 842653.	2.2	7
10	Intermittent PI3K inhibition sustains anti-tumour immunity and curbs irAEs. <i>Nature</i> , 2022, 605, 741-746.	13.7	36
11	Abstract CT213: A multicenter phase 1a/b study of NG-350A, a tumor-selective anti-CD40-antibody expressing adenoviral vector, and pembrolizumab in patients with metastatic or advanced epithelial tumors (FORTIFY). <i>Cancer Research</i> , 2022, 82, CT213-CT213.	0.4	1
12	Abstract CT214: A multicenter phase 1a/b study of NG-641, a tumor-selective transgene-expressing adenoviral vector, and nivolumab in patients with metastatic or advanced epithelial tumors (NEBULA). <i>Cancer Research</i> , 2022, 82, CT214-CT214.	0.4	1
13	Tissue resident memory T cells (TRM) in primary, metastatic and recurrent head and neck squamous cell carcinoma (HNSCC) tissue. <i>Laryngo- Rhino- Otologie</i> , 2022, , .	0.2	0
14	Gewebsansässige Gedächtnis-T-Zellen (TRM) in primärem, metastasiertem und rezidivierendem Plattenepithelkarzinom des Kopfes und Halses (HNSCC). <i>Laryngo- Rhino- Otologie</i> , 2022, , .	0.2	0
15	NEBULA: A multicenter phase 1a/b study of a tumor-selective transgene-expressing adenoviral vector, NG-641, and nivolumab in patients with metastatic or advanced epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS2682-TPS2682.	0.8	1
16	FOCUS phase 3 trial results: Percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A).. <i>Journal of Clinical Oncology</i> , 2022, 40, 9510-9510.	0.8	22
17	Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. <i>International Immunopharmacology</i> , 2022, 110, 108985.	1.7	14
18	Prospective longitudinal study of immune checkpoint molecule (ICM) expression in immune cell subsets during curative conventional therapy of head and neck squamous cell carcinoma (HNSCC). <i>International Journal of Cancer</i> , 2021, 148, 2023-2035.	2.3	6

#	ARTICLE	IF	CITATIONS
19	Melanoma-reactive T cells take up residence. <i>Nature Cancer</i> , 2021, 2, 253-255.	5.7	1
20	An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS9138-TPS9138.	0.8	2
21	Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. <i>Nature Immunology</i> , 2021, 22, 1052-1063.	7.0	61
22	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. <i>BMC Cancer</i> , 2021, 21, 761.	1.1	12
23	Early-Phase Interventional Trials in Oral Cancer Prevention. <i>Cancers</i> , 2021, 13, 3845.	1.7	7
24	Automated Analysis of Proliferating Cells Spatial Organisation Predicts Prognosis in Lung Neuroendocrine Neoplasms. <i>Cancers</i> , 2021, 13, 4875.	1.7	7
25	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2-reactive CD8 ⁺ T cells. <i>Science Immunology</i> , 2021, 6, .	5.6	185
26	DNA Vaccines Targeting Novel Cancer-Associated Antigens Frequently Expressed in Head and Neck Cancer Enhance the Efficacy of Checkpoint Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 763086.	2.2	9
27	Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1530-1540.	5.1	130
28	COVID-19 genetic risk variants are associated with expression of multiple genes in diverse immune cell types. <i>Nature Communications</i> , 2021, 12, 6760.	5.8	32
29	CTEN Induces Tumour Cell Invasion and Survival and Is Prognostic in Radiotherapy-Treated Head and Neck Cancer. <i>Cancers</i> , 2020, 12, 2963.	1.7	5
30	Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4 ⁺ T Cells in COVID-19. <i>Cell</i> , 2020, 183, 1340-1353.e16.	13.5	431
31	M1 ^{hot} tumor-associated macrophages boost tissue-resident memory T cells infiltration and survival in human lung cancer. , 2020, 8, e000778.		99
32	HNSCC: Tumour Antigens and Their Targeting by Immunotherapy. <i>Cells</i> , 2020, 9, 2103.	1.8	48
33	CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. , 2020, 8, e000473.		31
34	Novel players: tissue-resident memory B cells. <i>Blood</i> , 2020, 136, 2722-2723.	0.6	2
35	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
36	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	2.9	51

#	ARTICLE	IF	CITATIONS
37	Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 895-904.	5.2	111
38	NOX4 Inhibition Potentiates Immunotherapy by Overcoming Cancer-Associated Fibroblast-Mediated CD8 T-cell Exclusion from Tumors. <i>Cancer Research</i> , 2020, 80, 1846-1860.	0.4	189
39	Paracrine SPARC signaling dysregulates alveolar epithelial barrier integrity and function in lung fibrosis. <i>Cell Death Discovery</i> , 2020, 6, 54.	2.0	23
40	Immune checkpoint inhibitors in advanced nasopharyngeal carcinoma: Beyond an era of chemoradiation?. <i>International Journal of Cancer</i> , 2020, 146, 2305-2314.	2.3	44
41	Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC. <i>Frontiers in Oncology</i> , 2020, 10, 591063.	1.3	3
42	Single-Cell Transcriptomic Analysis of SARS-CoV-2 Reactive CD4 ⁺ T Cells. <i>SSRN Electronic Journal</i> , 2020, , 3641939.	0.4	31
43	Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF- $\hat{\pm}$. <i>ELife</i> , 2020, 9, .	2.8	76
44	Abstract CT301: A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. <i>Cancer Research</i> , 2020, 80, CT301-CT301.	0.4	31
45	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2020, , 761-783.		1
46	Abstract PO-039: Spatially discrete signalling niches regulate fibroblast heterogeneity in human lung cancer. , 2020, , .		0
47	Paracrine signalling during ZEB1-mediated epithelial $\hat{\text{e}}$ mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. <i>Cell Death and Differentiation</i> , 2019, 26, 943-957.	5.0	104
48	Autophagy inhibition-mediated epithelial $\hat{\text{e}}$ mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis. <i>Cell Death and Disease</i> , 2019, 10, 591.	2.7	107
49	An optimised tissue disaggregation and data processing pipeline for characterising fibroblast phenotypes using single-cell RNA sequencing. <i>Scientific Reports</i> , 2019, 9, 9580.	1.6	46
50	Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. <i>Journal of Experimental Medicine</i> , 2019, 216, 2128-2149.	4.2	160
51	HPV Epitope Processing Differences Correlate with ERAP1 Allotype and Extent of CD8+ T-cell Tumor Infiltration in OPSCC. <i>Cancer Immunology Research</i> , 2019, 7, 1202-1213.	1.6	24
52	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 1255-1268.	2.5	45
53	Neoantigen-directed immune escape in lung cancer evolution. <i>Nature</i> , 2019, 567, 479-485.	13.7	639
54	Recent advances in the molecular landscape of lung neuroendocrine tumors. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 281-297.	1.5	38

#	ARTICLE	IF	CITATIONS
55	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. <i>Oncolmmunology</i> , 2019, 8, e1593810.	2.1	44
56	Recurrent group A <i>Streptococcus</i> tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant T _{FH} cells. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	90
57	Importance of the immune system in head and neck cancer. <i>Head and Neck</i> , 2019, 41, 2789-2800.	0.9	28
58	The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. <i>BMJ Open</i> , 2019, 9, e031531.	0.8	12
59	Actively personalized vaccination trial for newly diagnosed glioblastoma. <i>Nature</i> , 2019, 565, 240-245.	13.7	637
60	HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 356-367.	2.9	41
61	An Optimized Method to Isolate Human Fibroblasts from Tissue for Ex Vivo Analysis. <i>Bio-protocol</i> , 2019, 9, e3440.	0.2	0
62	Abstract A020: Immunomonitoring for actively personalized peptide vaccines (APVACs) during immunotherapeutic treatment of glioblastoma. , 2019, , .		0
63	Abstract B139: Plant viral particle vaccine induces a potent antitumor response through induction of antigen-specific T-cells and overcoming an immunosuppressive tumor microenvironment. , 2019, , .		0
64	Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. , 2019, , .		0
65	Abstract 1466: Combination immunotherapy successfully control tumor growth in a transgenic mouse model. , 2019, , .		0
66	Abstract 3762: Single-cell analysis of cancer-associated fibroblast heterogeneity in non-small cell lung cancer: Mapping molecular phenotypes in tumors. , 2019, , .		5
67	Real-world use of anti-PD-1 checkpoint inhibitors in the management of non-small cell lung cancer: experience from a large UK teaching hospital. <i>Lung Cancer</i> , 2018, 115, S35.	0.9	0
68	Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial. <i>Oncolmmunology</i> , 2018, 7, e1433516.	2.1	31
69	Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease. <i>Journal of Surgical Oncology</i> , 2018, 117, 1170-1178.	0.8	65
70	Assessment of neuronal autoantibodies in patients with small cell lung cancer treated with chemotherapy with or without ipilimumab. <i>Oncolmmunology</i> , 2018, 7, e1395125.	2.1	26
71	Linear doggybone DNA vaccine induces similar immunological responses to conventional plasmid DNA independently of immune recognition by TLR9 in a pre-clinical model. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 627-638.	2.0	28
72	Targeting the Myofibroblastic Cancer-Associated Fibroblast Phenotype Through Inhibition of NOX4. <i>Journal of the National Cancer Institute</i> , 2018, 110, 109-120.	3.0	134

#	ARTICLE	IF	CITATIONS
73	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 233.	0.7	41
74	Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies. <i>Cancer Cell</i> , 2018, 33, 649-663.e4.	7.7	448
75	Validation of Immunomonitoring Methods for Application in Clinical Studies: The HLA Peptide Multimer Staining Assay. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 342-353.	0.7	12
76	BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY. <i>Retinal Cases and Brief Reports</i> , 2018, 12, 184-187.	0.3	15
77	Immunotherapy in the immunodeficient: A treatment paradox?. <i>Annals of Oncology</i> , 2018, 29, viii429.	0.6	0
78	CONFIRM: a phase III randomised trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma. <i>Lung Cancer</i> , 2018, 115, S84.	0.9	0
79	ATIM-20. GAPVAC-101 TRIAL OF A HIGHLY PERSONALIZED PEPTIDE VACCINATION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi5-vi5.	0.6	0
80	Pembrolizumab in performance status 2 patients with non-small cell lung cancer (NSCLC): Results of the PePS2 trial. <i>Annals of Oncology</i> , 2018, 29, viii497.	0.6	12
81	Nanoscale dysregulation of collagen structure-function disrupts mechano-homeostasis and mediates pulmonary fibrosis. <i>ELife</i> , 2018, 7, .	2.8	99
82	CD103+CD8+ Lymphocytes Characterize the Immune Infiltration in a Case With Pseudoprogression in Squamous NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, e193-e196.	0.5	29
83	Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma. <i>Molecular and Cellular Proteomics</i> , 2018, 17, 2132-2145.	2.5	41
84	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. <i>Future Oncology</i> , 2018, 14, 2415-2431.	1.1	24
85	Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. <i>Annals of Oncology</i> , 2018, 29, 1843-1852.	0.6	47
86	Implications of Tuberculosis Reactivation after Immune Checkpoint Inhibition. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1451-1453.	2.5	54
87	GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2000-2000.	0.8	17
88	A randomised, double-blind, placebo-controlled phase IIa trial of AMG319 given orally as neoadjuvant therapy in patients with human papillomavirus (HPV) positive and negative head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6068-6068.	0.8	4
89	Immunotherapy in metastatic melanoma: When is it safe to stop?. <i>Journal of Clinical Oncology</i> , 2018, 36, e21518-e21518.	0.8	0
90	CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8586-TPS8586.	0.8	0

#	ARTICLE	IF	CITATIONS
91	Abstract 5084: Characterizing heterogeneity in the cancer-associated fibroblast population in non-small cell lung cancer: Relating phenotype to function. , 2018, , .		2
92	Abstract LB-143: Th1/Th2 and inflammatory cytokines as biomarkers of response to ipilimumab in small cell lung cancer (SCLC) patients. , 2018, , .		0
93	Exosomal microRNAs in the lung: eliciting long-term intercellular communication?. , 2018, , .		0
94	Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pravastatin Added to First-Line Standard Chemotherapy in Small-Cell Lung Cancer (LUNGSTAR). Journal of Clinical Oncology, 2017, 35, 1506-1514.	0.8	92
95	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Immunity, 2017, 46, 577-586.	6.6	323
96	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 2017, 545, 446-451.	13.7	1,287
97	Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nature Immunology, 2017, 18, 940-950.	7.0	407
98	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell, 2017, 171, 1259-1271.e11.	13.5	968
99	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. Clinical Cancer Research, 2017, 23, 7641-7649.	3.2	22
100	Towards personalised medicine in lung and thymus neuroendocrine tumours. Lancet Oncology, The, 2017, 18, 1563-1565.	5.1	1
101	Evaluating the effect of immune cells on the outcome of patients with mesothelioma. British Journal of Cancer, 2017, 117, 1341-1348.	2.9	47
102	COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. European Journal of Cancer, 2017, 87, 75-83.	1.3	24
103	PUB035 CONFIRM: A Phase III Randomized Trial to Evaluate the Efficacy of Nivolumab versus Placebo in Relapsed Mesothelioma. Journal of Thoracic Oncology, 2017, 12, S2376.	0.5	0
104	Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. Journal of Clinical Oncology, 2017, 35, TPS9099-TPS9099.	0.8	0
105	Abstract 2948: A distinct CD8+ tumor infiltrating lymphocyte subset is associated with high TIL density, enhanced cytotoxicity and improved survival in patients with lung cancer. , 2017, , .		0
106	Transcriptomic profiling reveals M1-high tumour associated macrophages that orchestrate the adaptive Anti-tumour response in human lung cancer. , 2017, , .		0
107	Mucosal-Associated Invariant T (MAIT) Cells Are Impaired in Th17 Associated Primary and Secondary Immunodeficiencies. PLoS ONE, 2016, 11, e0155059.	1.1	4
108	Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors. Oncotarget, 2016, 7, 56781-56797.	0.8	86

#	ARTICLE	IF	CITATIONS
109	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 651-662.	2.0	91
110	Upregulated Glucose Metabolism Correlates Inversely with CD8+ T-cell Infiltration and Survival in Squamous Cell Carcinoma. <i>Cancer Research</i> , 2016, 76, 4136-4148.	0.4	83
111	Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical Outcomes. <i>Clinical Cancer Research</i> , 2016, 22, 4827-4836.	3.2	24
112	TG4010: a vaccine with a therapeutic role in cancer. <i>Immunotherapy</i> , 2016, 8, 511-519.	1.0	14
113	Human Papillomavirus Drives Tumor Development Throughout the Head and Neck: Improved Prognosis Is Associated With an Immune Response Largely Restricted to the Oropharynx. <i>Journal of Clinical Oncology</i> , 2016, 34, 4132-4141.	0.8	105
114	Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination. <i>Current Topics in Microbiology and Immunology</i> , 2016, 405, 123-143.	0.7	6
115	Evaluation of immune infiltration in the colonic mucosa of patients with ipilimumab-related colitis. <i>Oncolmmunology</i> , 2016, 5, e1209615.	2.1	14
116	A plant-expressed conjugate vaccine breaks CD4 ⁺ tolerance and induces potent immunity against metastatic Her2 ⁺ breast cancer. <i>Oncolmmunology</i> , 2016, 5, e1166323.	2.1	36
117	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	0.5	95
118	Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 161-169.	2.0	175
119	Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma. <i>Oncolmmunology</i> , 2016, 5, e1143997.	2.1	74
120	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 212-223.	5.1	158
121	Abstract 2654: GAPVAC-101 phase I trial: First data of an innovative actively personalized peptide vaccination trial in patients with newly diagnosed glioblastoma. , 2016, , .		1
122	Induction of fibroblast senescence generates a non-fibroblastic myofibroblast phenotype that differentially impacts on cancer prognosis. <i>Aging</i> , 2016, 9, 114-132.	1.4	86
123	Wilms's tumour antigen 1 Immunity via DNA fusion gene vaccination in haematological malignancies by intramuscular injection followed by intramuscular electroporation: a Phase II non-randomised clinical trial (WIN). <i>Efficacy and Mechanism Evaluation</i> , 2016, 3, 1-80.	0.9	7
124	LSC Abstract " Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. , 2016, , .		0
125	LSC Abstract " Transcriptomic profiling of macrophages isolated from human non-small cell lung carcinoma (NSCLC) reveals novel macrophage subsets with distinct tumour response features. , 2016, , .		0
126	Ipilimumab in the real world. <i>Melanoma Research</i> , 2015, 25, 432-442.	0.6	50

#	ARTICLE	IF	CITATIONS
127	Plant Virus Particles Carrying Tumour Antigen Activate TLR7 and Induce High Levels of Protective Antibody. PLoS ONE, 2015, 10, e0118096.	1.1	58
128	Vaccination Expands Antigen-Specific CD4+ Memory T Cells and Mobilizes Bystander Central Memory T Cells. PLoS ONE, 2015, 10, e0136717.	1.1	23
129	Novel Approaches for Vaccination Against HPV-Induced Cancers. Current Topics in Microbiology and Immunology, 2015, 405, 33-53.	0.7	1
130	Infliximab for IPILIMUMAB-Related Colitis Letter. Clinical Cancer Research, 2015, 21, 5642-5643.	3.2	47
131	Staging and treatment of oropharyngeal cancer in the human papillomavirus era. Head and Neck, 2015, 37, 1002-1013.	0.9	49
132	Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. British Journal of Cancer, 2015, 113, 107-118.	2.9	34
133	Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters. Cancer Immunology, Immunotherapy, 2015, 64, 585-598.	2.0	18
134	Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study. Cancer Immunology, Immunotherapy, 2015, 64, 1021-1032.	2.0	27
135	Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study. Clinical Cancer Research, 2015, 21, 1321-1328.	3.2	81
136	Immunosuppression for ipilimumab-related toxicity can cause <i>pneumocystis</i> pneumonia but spare antitumor immune control. Oncoimmunology, 2015, 4, e1040218.	2.1	39
137	Uveal Melanoma UK National Guidelines. European Journal of Cancer, 2015, 51, 2404-2412.	1.3	89
138	NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus. International Journal of Cancer, 2015, 136, E590-601.	2.3	46
139	An adjuvant clinical trial of SCIB1, a DNA vaccine that targets dendritic cells <i>in vivo</i> , in fully resected melanoma patients.. Journal of Clinical Oncology, 2015, 33, 9035-9035.	0.8	1
140	Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastatic uveal melanoma.. Journal of Clinical Oncology, 2015, 33, e20000-e20000.	0.8	4
141	Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. , 2015, , 471-490.		1
142	The immune response in HPV ⁺ oropharyngeal cancer. Oncoimmunology, 2014, 3, e27254.	2.1	32
143	A Phase I/II, Multiple-Dose, Dose-Escalation Study of Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2014, 20, 2192-2204.	3.2	147
144	Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases. Journal of the National Cancer Institute, 2014, 106, .	3.0	105

#	ARTICLE	IF	CITATIONS
145	Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer. <i>British Journal of Cancer</i> , 2014, 110, 489-500.	2.9	326
146	Anti-CTLA-4 therapy broadens the melanoma-reactive CD8 ⁺ T cell response. <i>Science Translational Medicine</i> , 2014, 6, 254ra128.	5.8	325
147	Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8 ⁺ T cells with detection by ELISPOT and HLA-multimer staining. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1199-1211.	2.0	30
148	Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme. <i>European Journal of Cancer</i> , 2014, 50, 1717-1721.	1.3	12
149	The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. <i>European Journal of Surgical Oncology</i> , 2014, 40, 1313-1320.	0.5	135
150	The role of the reporting framework MIATA within current efforts to advance immune monitoring. <i>Journal of Immunological Methods</i> , 2014, 409, 6-8.	0.6	4
151	DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. <i>Annals of Oncology</i> , 2014, 25, 968-974.	0.6	68
152	Suppression of Hedgehog signalling promotes pro-tumourigenic integrin expression and function. <i>Journal of Pathology</i> , 2014, 233, 196-208.	2.1	7
153	Abstract CT331: Phase I/II trial of a novel antibody DNA immunotherapy, targeting CD64, in the treatment of Melanoma. , 2014, , .		1
154	Phase I trial of ImmunoBody in melanoma patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3061-3061.	0.8	2
155	FOXO3 expression during colorectal cancer progression: biomarker potential reflects a tumour suppressor role. <i>British Journal of Cancer</i> , 2013, 109, 387-394.	2.9	72
156	Genetic Vaccines against Cancer. , 2013, , 223-239.		1
157	Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 615-627.	2.0	27
158	The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 489-501.	2.0	16
159	Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). <i>European Journal of Cancer</i> , 2013, 49, 2815-2822.	1.3	45
160	Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). <i>Annals of Oncology</i> , 2013, 24, 2875-2880.	0.6	48
161	New horizons for prostate cancer: part 2. <i>Trends in Urology & Men's Health</i> , 2013, 4, 13-16.	0.2	0
162	New horizons for prostate cancer: part 1. <i>Trends in Urology & Men's Health</i> , 2013, 4, 38-40.	0.2	0

#	ARTICLE	IF	CITATIONS
163	Abstract LB-142: A trial of agonistic anti-CD40 antibody: Biological effects in a Cancer Research UK phase I study.. , 2013, , .		1
164	A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. <i>Chemotherapy</i> , 2012, 58, 257-263.	0.8	5
165	DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 2161-2170.	2.0	89
166	T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. <i>Immunity</i> , 2012, 37, 1-2.	6.6	131
167	The adaptive immune response to colorectal cancer: From the laboratory to clinical practice. <i>European Journal of Surgical Oncology</i> , 2012, 38, 889-896.	0.5	16
168	Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 66.	1.0	55
169	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	1.8	676
170	Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2012, 367, 107-114.	13.9	1,976
171	Harmonization of the intracellular cytokine staining assay. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 967-978.	2.0	47
172	CD8 ⁺ T cell cross-competition is governed by peptide-MHC class I stability. <i>European Journal of Immunology</i> , 2012, 42, 256-263.	1.6	28
173	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS8605-TPS8605.	0.8	1
174	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139
175	Harmonization of Immune Biomarker Assays for Clinical Studies. <i>Science Translational Medicine</i> , 2011, 3, 108ps44.	5.8	87
176	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
177	119 Phase I dose finding study of irinotecan in combination with carboplatin in treatment naive extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2011, 71, S41.	0.9	0
178	DNA fusion vaccines enter the clinic. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1147-1151.	2.0	21
179	DNA fusion gene vaccines induce cytotoxic T cell attack on naturally processed peptides of human prostate-specific membrane antigen. <i>European Journal of Immunology</i> , 2011, 41, 2447-2456.	1.6	15
180	Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies. <i>British Journal of Cancer</i> , 2011, 105, 353-359.	2.9	48

#	ARTICLE	IF	CITATIONS
181	A randomised, phase II study of intetumumab, an anti- α v-integrin mAb, alone and with dacarbazine in stage IV melanoma. <i>British Journal of Cancer</i> , 2011, 105, 346-352.	2.9	108
182	T-cell immune monitoring assays to guide the development of new cancer vaccines. , 2011, , 156-166.		0
183	Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 863-873.	2.0	53
184	Serum is not required for ex vivo IFN- γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 619-627.	2.0	29
185	Response definition criteria for ELISPOT assays revisited. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1489-1501.	2.0	188
186	DNA vaccines against cancer come of age. <i>Current Opinion in Immunology</i> , 2010, 22, 264-270.	2.4	63
187	Ig gene diversification and selection in follicular lymphoma, diffuse large B cell lymphoma and primary central nervous system lymphoma revealed by lineage tree and mutation analyses. <i>International Immunology</i> , 2010, 22, 875-887.	1.8	38
188	Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2010, 363, 711-723.	13.9	13,065
189	Melanoma sentinel node biopsy and prediction models for relapse and overall survival. <i>British Journal of Cancer</i> , 2010, 103, 1229-1236.	2.9	54
190	Randomized Double-Blind Placebo-Controlled Trial of Thalidomide in Combination With Gemcitabine and Carboplatin in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5248-5254.	0.8	65
191	The Synthesis and <i>in vivo</i> Evaluation of 2,2-Difluoro KRN7000. <i>ChemMedChem</i> , 2009, 4, 329-334.	1.6	21
192	First case report of Muir-Torre syndrome associated with non-small cell lung cancer. <i>Familial Cancer</i> , 2009, 8, 359-362.	0.9	20
193	Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 789-800.	2.0	16
194	DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. <i>Human Gene Therapy</i> , 2009, 20, 1269-1278.	1.4	172
195	Defining Multiple Myeloma as a Target for DNA Fusion Gene Vaccines. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S23-S24.	1.4	1
196	Primary central nervous system lymphoma: tumor-related clones exist in the blood and bone marrow with evidence for separate development. <i>Blood</i> , 2009, 113, 4677-4680.	0.6	56
197	The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 289-302.	2.0	138
198	Synthesis and <i>in vitro</i> Evaluation of GalCer Epimers. <i>ChemMedChem</i> , 2008, 3, 1061-1070.	1.6	33

#	ARTICLE	IF	CITATIONS
199	Survival from melanoma of the skin in England and Wales up to 2001. <i>British Journal of Cancer</i> , 2008, 99, S50-S52.	2.9	3
200	DNA vaccines: precision tools for activating effective immunity against cancer. <i>Nature Reviews Cancer</i> , 2008, 8, 108-120.	12.8	388
201	Remarkable selective glycosylation of the immunoglobulin variable region in follicular lymphoma. <i>Molecular Immunology</i> , 2008, 45, 1567-1572.	1.0	52
202	Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. <i>Lancet, The</i> , 2008, 371, 1685-1694.	6.3	250
203	Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. <i>Lancet, The</i> , 2008, 372, 117-126.	6.3	620
204	Synthesis and In Vivo Evaluation of 4-Deoxy-4,4-difluoro-KRN7000. <i>Organic Letters</i> , 2008, 10, 4433-4436.	2.4	30
205	Taking Electroporation-Based Delivery of DNA Vaccination into Humans: A Generic Clinical Protocol. <i>Methods in Molecular Biology</i> , 2008, 423, 497-507.	0.4	15
206	Cancer Vaccines. , 2007, , 183-204.		4
207	C1-03: A phase III randomised, double blind, placebo controlled trial of gemcitabine/carboplatin with or without thalidomide in advanced non-small cell lung cancer (NSCLC). <i>Journal of Thoracic Oncology</i> , 2007, 2, S359.	0.5	4
208	Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. <i>British Journal of Cancer</i> , 2006, 94, 1383-1388.	2.9	53
209	Universal N-glycosylation sites introduced into the B-cell receptor of follicular lymphoma by somatic mutation: a second tumorigenic event?. <i>Leukemia</i> , 2006, 20, 530-534.	3.3	31
210	Immunoglobulin Heavy Chain Locus Events and Expression of Activation-Induced Cytidine Deaminase in Epithelial Breast Cancer Cell Lines. <i>Cancer Research</i> , 2006, 66, 3996-4000.	0.4	119
211	Idiotype Gene Rescue in Follicular Lymphoma. , 2005, 115, 145-172.		1
212	DNA vaccines to attack cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 14646-14652.	3.3	109
213	DNA fusion gene vaccines against cancer: from the laboratory to the clinic. <i>Immunological Reviews</i> , 2004, 199, 156-180.	2.8	78
214	Dose Seeking Evaluation of a Novel Heterologous Primeboost Immunotherapy in Stage III and IV Metastatic Melanoma Patients. <i>Journal of Immunotherapy</i> , 2004, 27, S27.	1.2	0
215	Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , 2003, 30, 136-141.	0.8	37
216	Incidence of potential glycosylation sites in immunoglobulin variable regions distinguishes between subsets of Burkitt's lymphoma and mucosa-associated lymphoid tissue lymphoma. <i>British Journal of Haematology</i> , 2003, 120, 217-222.	1.2	56

#	ARTICLE	IF	CITATIONS
217	Anti-idiotypic vaccines. <i>British Journal of Haematology</i> , 2003, 123, 770-781.	1.2	27
218	Vaccine Therapy in NHL: Future Promises and Current Limitations. <i>Leukemia and Lymphoma</i> , 2003, 44, S85-S90.	0.6	2
219	Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. <i>Blood</i> , 2002, 99, 2562-2568.	0.6	237
220	Typical Waldenstrom macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events. <i>Blood</i> , 2002, 100, 1505-1507.	0.6	105
221	The occurrence and significance of V gene mutations in B cell-derived human malignancy. <i>Advances in Cancer Research</i> , 2001, 83, 81-116.	1.9	95
222	The classification of lymphomas and leukemias. <i>Chemico-Biological Interactions</i> , 2001, 135-136, 653-664.	1.7	13
223	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. <i>Blood</i> , 2000, 96, 2550-2556.	0.6	12
224	Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. <i>Blood</i> , 2000, 96, 2550-2556.	0.6	4
225	Immunocytochemical assessment of bone marrow aspirates for monitoring response to chemotherapy in small-cell lung cancer patients. <i>British Journal of Cancer</i> , 1999, 81, 1213-1221.	2.9	12
226	Insight into the origin and clonal history of B-cell tumors as revealed by analysis of immunoglobulin variable region genes. <i>Immunological Reviews</i> , 1998, 162, 247-259.	2.8	132
227	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. <i>Blood</i> , 1998, 91, 4292-4299.	0.6	133
228	Analysis of VH Genes in Follicular and Diffuse Lymphoma Shows Ongoing Somatic Mutation and Multiple Isotype Transcripts in Early Disease With Changes During Disease Progression. <i>Blood</i> , 1998, 91, 4292-4299.	0.6	6
229	Absence of constitutive EGF receptor activation in ovarian cancer cell lines. <i>British Journal of Cancer</i> , 1996, 74, 446-452.	2.9	18
230	Histological transformation of indolent (follicular) lymphoma. <i>Annals of Oncology</i> , 1996, 7, 849-853.	0.6	3
231	CD44 variant expression is a common feature of epithelial ovarian cancer: lack of association with standard prognostic factors. <i>Journal of Clinical Oncology</i> , 1995, 13, 1912-1921.	0.8	84
232	Expression and Function of $\alpha 21$ and $\alpha v\beta 3$ Integrins in Ovarian Cancer. <i>Gynecologic Oncology</i> , 1995, 58, 216-225.	0.6	135
233	Treatment of advanced chronic lymphocytic leukemia by fludarabine. <i>Annals of Hematology</i> , 1991, 63, 1-4.	0.8	80
234	T _H 1 Cells Inhibit Anti-Tumor Immunity and are Responsive to Immune Checkpoint Blockade. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1